Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection

New campaign connects AI-powered performance insights linking advanced molecular intelligence to help detect cancer in earlier stages IRVING, Texas, Oct. 19, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the launch of the second commercial in a series promoting Caris Detect™, Caris' multi-cancer early detection (MCED) test, featuring three-time major champion professional golfer, Jordan Spieth. The campaign emphasizes that while modern technology can measure nearly every aspect of athletic performance, the same level of intelligence can be applied to helping people find early stage cancer – when treatment is most effective.

PRNewsWire • Oct 19, 2026

Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

IRVING, Texas, Oct. 15, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced it will report third quarter 2026 financial results on Wednesday, November 4, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m.

PRNewsWire • Oct 15, 2026

Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026

Eight posters will feature AI-driven approaches to treatment prediction, risk stratification and biomarker discovery advancing precision medicine across multiple cancer types IRVING, Texas, Oct. 14, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present eight posters at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The research showcases the expanding impact of artificial intelligence, molecular profiling and multimodal data integration in advancing precision oncology across multiple tumor types.

PRNewsWire • Oct 14, 2026

IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months

Caris stock is pulling back after more than doubling in just two months. Wait for the IPO stock to offer a new buy point.

Investors Business Daily • Oct 2, 2026

FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.

Grail's Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.

Market Watch • Sep 23, 2026

Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look

Wall Street projects the company turning a net profit of 12 cents a share this year.

Investors Business Daily • Sep 22, 2026

Caris Life Sciences: Diagnostics Growth With Room To Run

Caris Life Sciences has an already established profiling business that provides revenue and cash flows for its expanding diagnostics portfolio. CAI reuses molecular data and clinical relationships, leveraging them into new tests that I believe should increase their shareholder value in the long run. CAI's Detect broadens its growth potential. However, we still need to see if their cash-pay adoption and marketing expenses pay off as intended.

Seeking Alpha • Sep 17, 2026

Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?

Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Sep 16, 2026

Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect

New partnership highlights the importance of finding cancer earlier through Caris Detect, a multi-cancer early detection blood test now available nationwide IRVING, Texas, Sept. 8, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced the launch of its new national campaign titled, "Math," featuring the iconic, award-winning actor, producer and director, Kevin Costner.

PRNewsWire • Sep 8, 2026

Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer

Seven studies will be presented, including two mini oral presentations and a poster tour presentation IRVING, Texas, Sept. 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present seven studies at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), taking place September 12-15, 2026, in Seoul, South Korea.

PRNewsWire • Sep 2, 2026